202 related articles for article (PubMed ID: 35624009)
1. Therapeutic potential of interleukin-2 in autoimmune diseases.
Yuan Y; Kolios AGA; Liu Y; Zhang B; Li H; Tsokos GC; Zhang X
Trends Mol Med; 2022 Jul; 28(7):596-612. PubMed ID: 35624009
[TBL] [Abstract][Full Text] [Related]
2. Fine tuning subsets of CD4
Zhao Z; Zhang X; Su L; Xu L; Zheng Y; Sun J
Int Immunopharmacol; 2018 Mar; 56():269-276. PubMed ID: 29414661
[TBL] [Abstract][Full Text] [Related]
3. Low-dose IL-2 therapy in autoimmune diseases: An update review.
Zhang R; Zhao Y; Chen X; Zhuang Z; Li X; Shen E
Int Rev Immunol; 2024 May; 43(3):113-137. PubMed ID: 37882232
[TBL] [Abstract][Full Text] [Related]
4. Molecular Engineering of Interleukin-2 for Enhanced Therapeutic Activity in Autoimmune Diseases.
Tomasovic LM; Liu K; VanDyke D; Fabilane CS; Spangler JB
BioDrugs; 2024 Mar; 38(2):227-248. PubMed ID: 37999893
[TBL] [Abstract][Full Text] [Related]
5. Low-dose interleukin-2 therapy: a driver of an imbalance between immune tolerance and autoimmunity.
Kosmaczewska A
Int J Mol Sci; 2014 Oct; 15(10):18574-92. PubMed ID: 25322151
[TBL] [Abstract][Full Text] [Related]
6. Low-dose interleukin-2 as a modulator of Treg homeostasis after HSCT: current understanding and future perspectives.
Matsuoka KI
Int J Hematol; 2018 Feb; 107(2):130-137. PubMed ID: 29234980
[TBL] [Abstract][Full Text] [Related]
7. Low-Dose IL-2 in the Treatment of Lupus.
Mizui M; Tsokos GC
Curr Rheumatol Rep; 2016 Nov; 18(11):68. PubMed ID: 27734211
[TBL] [Abstract][Full Text] [Related]
8. Rapamycin nanoparticles increase the therapeutic window of engineered interleukin-2 and drive expansion of antigen-specific regulatory T cells for protection against autoimmune disease.
Kishimoto TK; Fournier M; Michaud A; Rizzo G; Roy C; Capela T; Nukolova N; Li N; Doyle L; Fu FN; VanDyke D; Traber PG; Spangler JB; Leung SS; Ilyinskii PO
J Autoimmun; 2023 Nov; 140():103125. PubMed ID: 37844543
[TBL] [Abstract][Full Text] [Related]
9. New therapeutic strategies based on IL-2 to modulate Treg cells for autoimmune diseases.
Xu L; Song X; Su L; Zheng Y; Li R; Sun J
Int Immunopharmacol; 2019 Jul; 72():322-329. PubMed ID: 31005777
[TBL] [Abstract][Full Text] [Related]
10. New Molecular and Cellular Mechanisms of Tolerance: Tolerogenic Actions of IL-2.
Pérol L; Piaggio E
Methods Mol Biol; 2016; 1371():11-28. PubMed ID: 26530792
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-2 and autoimmune disease occurrence and therapy.
Geng X; Zhang R; Yang G; Jiang W; Xu C
Eur Rev Med Pharmacol Sci; 2012 Oct; 16(11):1462-7. PubMed ID: 23111957
[TBL] [Abstract][Full Text] [Related]
12. IL-2- and CD25-dependent immunoregulatory mechanisms in the homeostasis of T-cell subsets.
Létourneau S; Krieg C; Pantaleo G; Boyman O
J Allergy Clin Immunol; 2009 Apr; 123(4):758-62. PubMed ID: 19348914
[TBL] [Abstract][Full Text] [Related]
13. Low-dose Interleukin-2: Biology and therapeutic prospects in rheumatoid arthritis.
Wu R; Li N; Zhao X; Ding T; Xue H; Gao C; Li X; Wang C
Autoimmun Rev; 2020 Oct; 19(10):102645. PubMed ID: 32801037
[TBL] [Abstract][Full Text] [Related]
14. Low-Dose IL-2 Therapy in Autoimmune and Rheumatic Diseases.
Graßhoff H; Comdühr S; Monne LR; Müller A; Lamprecht P; Riemekasten G; Humrich JY
Front Immunol; 2021; 12():648408. PubMed ID: 33868284
[TBL] [Abstract][Full Text] [Related]
15. Thymic commitment of regulatory T cells is a pathway of TCR-dependent selection that isolates repertoires undergoing positive or negative selection.
Coutinho A; Caramalho I; Seixas E; Demengeot J
Curr Top Microbiol Immunol; 2005; 293():43-71. PubMed ID: 15981475
[TBL] [Abstract][Full Text] [Related]
16. Modulation of T cell responses by IL-2 and IL-2 complexes.
Boyman O; Kolios AG; Raeber ME
Clin Exp Rheumatol; 2015; 33(4 Suppl 92):S54-7. PubMed ID: 26457438
[TBL] [Abstract][Full Text] [Related]
17. Low-dose interleukin-2 promotes STAT-5 phosphorylation, T
Jeffery HC; Jeffery LE; Lutz P; Corrigan M; Webb GJ; Hirschfield GM; Adams DH; Oo YH
Clin Exp Immunol; 2017 Jun; 188(3):394-411. PubMed ID: 28176332
[TBL] [Abstract][Full Text] [Related]
18. Beyond regulatory T cells: the potential role for IL-2 to deplete T-follicular helper cells and treat autoimmune diseases.
Ballesteros-Tato A
Immunotherapy; 2014; 6(11):1207-20. PubMed ID: 25496335
[TBL] [Abstract][Full Text] [Related]
19. "IL-2 immunotherapy for targeting regulatory T cells in autoimmunity".
Lykhopiy V; Malviya V; Humblet-Baron S; Schlenner SM
Genes Immun; 2023 Oct; 24(5):248-262. PubMed ID: 37741949
[TBL] [Abstract][Full Text] [Related]
20. Regulatory T Cell Responses in Participants with Type 1 Diabetes after a Single Dose of Interleukin-2: A Non-Randomised, Open Label, Adaptive Dose-Finding Trial.
Todd JA; Evangelou M; Cutler AJ; Pekalski ML; Walker NM; Stevens HE; Porter L; Smyth DJ; Rainbow DB; Ferreira RC; Esposito L; Hunter KM; Loudon K; Irons K; Yang JH; Bell CJ; Schuilenburg H; Heywood J; Challis B; Neupane S; Clarke P; Coleman G; Dawson S; Goymer D; Anselmiova K; Kennet J; Brown J; Caddy SL; Lu J; Greatorex J; Goodfellow I; Wallace C; Tree TI; Evans M; Mander AP; Bond S; Wicker LS; Waldron-Lynch F
PLoS Med; 2016 Oct; 13(10):e1002139. PubMed ID: 27727279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
